Duram Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 06-07-2024
- Company Age 30 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 11.10 Cr
as on 06-07-2024
- Revenue -37.65%
(FY 2021)
- Profit 19.35%
(FY 2021)
- Ebitda -6.25%
(FY 2021)
- Net Worth -14.18%
(FY 2021)
- Total Assets 0.20%
(FY 2021)
About Duram Pharmachem
The Corporate was formerly known as Dura Holdings Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company has closed loans amounting to ₹11.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rakesh Doshi and Usha Doshi serve as directors at the Company.
- CIN/LLPIN
U65990MH1994PTC082503
- Company No.
082503
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Oct 1994
- Date of AGM
01 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Duram Pharmachem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Doshi  | Director | 28-Oct-1994 | Current |
| Usha Doshi | Director | 28-Oct-1994 | Current |
Financial Performance of Duram Pharmachem.
Duram Pharmachem Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 37.65% decrease. The company also saw a substantial improvement in profitability, with a 19.35% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Duram Pharmachem?
In 2021, Duram Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sicom Investments & Finance Limited Creation Date: 30 Aug 2012 | ₹10.00 Cr | Satisfied |
State Bank Of India Creation Date: 14 Jan 2011 | ₹1.10 Cr | Satisfied |
How Many Employees Work at Duram Pharmachem?
Duram Pharmachem has a workforce of 15 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duram Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duram Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
